Benchmark raised the firm’s price target on Halozyme (HALO) to $90 from $75 and keeps a Buy rating on the shares. The FDA has approved Merck’s (MRK) subcutaneous Keytruda Qlex, a large oncology drug that includes berahyaluronidase alpha-pmph, an enzyme licensed from Korean firm Alteogen that competes with Halozyme’s Enhanze enzyme, the analyst noted. The pending launch of SubQ Keytruda is expected to bring to a head the ongoing patent litigation between Halozyme and Merck, the analyst added.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HALO:
- Halozyme’s Strong Financial Performance and Strategic Positioning Justify Buy Rating Amid Patent Challenges
- Halozyme price target raised to $85 from $75 at H.C. Wainwright
- Halozyme price target raised to $80 from $75 at Morgan Stanley
- Halozyme’s Strong Financial Performance and Growth Potential Justifies Buy Rating
- Halozyme Therapeutics’ Earnings Call Highlights Robust Growth